All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which factors may impact transplantation outcomes in patients with MF?

During the 2021 ASCO Annual Meeting, the MPN Hub spoke with Jan Philipp Bewersdorf, Yale School of Medicine, New Haven, US. We asked, Which factors may impact transplantation outcomes in patients with myelofibrosis (MF)?

Which factors may impact transplantation outcomes in patients with MF?

Bewersdorf presents results from a systematic review and meta-analysis investigating whether allo-HCT should be considered for eligible patients with MF, and the importance of risk stratification.

Share: